Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluation of the Safety and Effectiveness of Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: Findings from a CIBMTR Study

  • By

  • Doris K. Hansen

  • Danai Dima

  • Hira Mian

  • Jakob Devos

  • Ruta Brazauskas

  • Temitope Oloyede

  • Aimaz Afrough

  • Nausheen Ahmed

  • Larry D. Anderson

  • Rahul Banerjee

  • Jesus G. Berdeja

  • Aram Bidikian

  • Binod Dhakal

  • Ajoy Dias

  • Yvonne Efebera

  • Muhammad Salman Faisal

  • Lohith Gowda

  • Hamza Hashmi

  • Abu-Sayeef Mirza

  • Meera Mohan

  • Ravi Narra

  • Ashley E. Rosko

  • Mark Schroeder

  • Taiga Nishihori

  • Heather Landau

  • Saad Usmani

  • Marcelo C. Pasquini

  • Othman S. Akhtar

  • Surbhi Sidana

  • Krina K. Patel

  • August 31, 2026

Share

Original Source(s)

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

  • by Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D. Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

  • August 31, 2026

Related Content

Cancer Communication in an Era of Fragmented Trust

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min